A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
$35.9B
Mkt Cap
$30.81
-1.19%
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a current P/E ratio of 25.5, compared to its historical median P/E of 24.5. The stock is currently considered Fair based on its historical valuation range.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a 5-year average return on invested capital (ROIC) of 3.2%. This is below average and may indicate limited pricing power.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a market capitalization of $35.9B. It is classified as a large-cap stock.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) does not currently pay a regular dividend.
Based on historical P/E analysis, TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) appears fair. The current P/E of 25.5 is 4% above its historical median of 24.5. The estimated fair value CAGR (P/E method) is 33.5%.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Business Overview We are a biopharmaceutical company, enabled by a world-class generics business. For over 120 years, our commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, we are dedicated to addressing patients’ needs, now and in the future. We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets. Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. Our Business Segments We operate our business through three segments: United States, Europe and International Markets.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.6B | 17.3B | 16.5B | 15.8B | 14.9B | 15.9B |
| Net Income | 1.6B | 1.4B | -1.6B | -559M | -2.4B | 417M |
| EPS | $1.36 | $1.21 | $-1.45 | $-0.50 | $-2.20 | $0.38 |
| Free Cash Flow | 1.2B | 1.1B | 749M | 842M | 1.0B | 236M |
| ROIC | 36.6% | 26.4% | -3.6% | 4.4% | -18.7% | 7.6% |
| Gross Margin | 567.8% | 51.8% | 48.7% | 48.2% | 46.7% | 47.8% |
| Debt/Equity | 0.32 | 0.82 | 0.74 | 0.95 | 0.53 | 0.93 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 2.3B | 2.2B | -303M | 433M | -2.2B | 1.7B |
| Operating Margin | 143.9% | 12.5% | -1.8% | 2.7% | -14.7% | 10.8% |
| ROE | 19.0% | 21.2% | -25.5% | -7.3% | -27.1% | 4.1% |
| Shares Outstanding | 1,164M | 1,165M | 1,130M | 1,118M | 1,112M | 1,097M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 20.3B | 19.7B | 21.9B | 22.4B | 18.3B | 16.9B | 16.7B | 15.9B | 14.9B | 15.8B | 16.5B | 17.3B | 1.6B |
| Gross Margin | 54.5% | 57.8% | 53.2% | 47.4% | 45.4% | 44.6% | 46.4% | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% | 567.8% |
| R&D | 0 | 35M | 422M | 175M | 114M | 1.0B | 997M | 967M | 98M | 953M | 998M | 1.0B | 988M |
| SG&A | 1.2B | 1.4B | 1.4B | 1.5B | 1.3B | 1.2B | 1.2B | 1.1B | 1.2B | 1.2B | 1.2B | 1.3B | 1.3B |
| EBIT | 4.0B | 3.4B | 2.2B | -17.5B | -1.6B | -443M | -3.6B | 1.7B | -2.2B | 433M | -303M | 2.2B | 2.3B |
| Op. Margin | 19.5% | 17.1% | 9.8% | -78.1% | -9.0% | -2.6% | -21.4% | 10.8% | -14.7% | 2.7% | -1.8% | 12.5% | 143.9% |
| Net Income | 3.1B | 1.6B | 329M | -16.5B | -2.4B | -999M | -4.0B | 417M | -2.4B | -559M | -1.6B | 1.4B | 1.6B |
| Net Margin | 15.1% | 8.0% | 1.5% | -73.8% | -13.1% | -5.9% | -24.0% | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% | 98.4% |
| Non-Recurring | 246M | 183M | 1.9B | 18.7B | 3.6B | 198M | 4.8B | 140M | 2.2B | 836M | 1.4B | 203M | 236M |
| Returns on Capital | |||||||||||||
| ROIC | 8.9% | 7.2% | 3.0% | -29.5% | -7.0% | -5.0% | -26.8% | 7.6% | -18.7% | 4.4% | -3.6% | 26.4% | 36.6% |
| ROE | 13.3% | 5.9% | 1.0% | -65.2% | -15.0% | -7.0% | -33.3% | 4.1% | -27.1% | -7.3% | -25.5% | 21.2% | 19.0% |
| ROA | 6.5% | 3.1% | 0.4% | -20.2% | -3.7% | -1.7% | -7.4% | 0.8% | -5.3% | -1.3% | -4.0% | 3.5% | 3.9% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 5.1B | 5.5B | 3.9B | 2.2B | 2.4B | 748M | 1.2B | 798M | 1.6B | 1.4B | 1.2B | 1.6B | 1.7B |
| Free Cash Flow | 4.2B | 4.8B | 3.0B | 1.4B | 1.8B | 223M | 638M | 236M | 1.0B | 842M | 749M | 1.1B | 1.2B |
| Owner Earnings | 1.7B | 1.9B | -87M | -2.4B | -2.6B | -4.3B | -470M | -651M | 158M | 94M | 65M | 490M | -3.2B |
| CapEx | 929M | 772M | 901M | 874M | 651M | 525M | 578M | 562M | 548M | 526M | 498M | 501M | 542M |
| Maint. CapEx | 3.3B | 3.5B | 3.9B | 4.5B | 4.9B | 4.9B | 1.6B | 1.3B | 1.3B | 1.2B | 1.1B | 1.0B | 4.7B |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 3.3B | 3.5B | 3.9B | 4.5B | 4.9B | 4.9B | 1.6B | 1.3B | 1.3B | 1.2B | 1.1B | 1.0B | 4.7B |
| CapEx/OCF | N/A | N/A | 17.2% | 39.3% | 26.6% | 70.2% | 47.5% | 70.4% | 34.5% | 38.5% | 39.9% | 30.4% | 31.6% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 1.2B | 1.2B | 1.3B | 901M | 12M | 52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | 2.4% | 3.5% | 0.1% | 0.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 500M | 439M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 95M | 117M | 124M | 133M | 155M | 119M | 129M | 119M | 124M | 121M | 123M | 157M | 166M |
| Debt Repayment | 839M | 2.5B | 999M | 3.3B | 7.4B | 3.9B | 1.9B | 6.6B | 1.4B | 4.2B | 1.6B | 4.1B | 4.1B |
| Balance Sheet | |||||||||||||
| Net Debt | 7.4B | 2.0B | 30.4B | 27.3B | 6.2B | 4.3B | 3.8B | 7.4B | 1.4B | 3.9B | 691M | 2.9B | -1.1B |
| Cash & Equiv. | 2.2B | 6.9B | 988M | 963M | 1.8B | 2.0B | 2.2B | 2.2B | 2.8B | 3.2B | 3.3B | 3.6B | 3.7B |
| Long-Term Debt | 8.6B | 8.4B | 32.5B | 28.8B | 7.4B | 3.9B | 1.9B | 6.6B | 1.4B | 4.2B | 1.6B | 4.1B | N/A |
| Debt/Equity | 0.42 | 0.32 | 1.00 | 1.83 | 0.60 | 0.48 | 0.60 | 0.93 | 0.53 | 0.95 | 0.74 | 0.82 | 0.32 |
| Interest Coverage | 13.2 | 12.4 | 3.9 | -20.0 | -1.8 | -0.5 | -4.0 | 1.9 | -2.4 | 0.4 | -0.3 | 2.4 | 2.5 |
| Equity | 23.3B | 29.8B | 33.3B | 17.4B | 14.7B | 14.0B | 10.0B | 10.3B | 7.8B | 7.5B | 5.4B | 7.9B | 8.2B |
| Total Assets | 46.4B | 54.2B | 93.1B | 70.6B | 60.7B | 57.5B | 50.6B | 47.7B | 44.0B | 43.5B | 39.3B | 40.7B | 40.0B |
| Total Liabilities | 23.1B | 24.3B | 58.1B | 51.9B | 44.9B | 42.4B | 39.6B | 36.4B | 35.4B | 35.4B | 33.6B | 32.8B | 31.8B |
| Intangibles | 5.5B | 7.7B | 21.5B | 17.6B | 14.0B | 11.2B | 8.9B | 7.5B | 6.3B | 5.4B | 4.4B | 3.8B | 3.6B |
| Retained Earnings | 14.4B | 14.9B | 13.6B | -3.8B | -6.0B | -7.0B | -10.9B | -10.5B | -13.0B | -13.5B | -15.2B | -13.8B | -13.4B |
| Working Capital | 2.1B | 5.4B | -1.3B | -2.5B | -528M | -210M | -159M | 1.5B | 582M | 238M | -244M | 490M | 178M |
| Current Assets | 14.4B | 18.4B | 17.2B | 15.4B | 13.8B | 13.5B | 13.0B | 12.6B | 12.1B | 12.5B | 12.6B | 13.9B | 13.7B |
| Current Liabilities | 12.3B | 13.0B | 18.5B | 17.9B | 14.3B | 13.7B | 13.2B | 11.0B | 11.5B | 12.2B | 12.8B | 13.5B | 13.5B |
| Per Share Data | |||||||||||||
| EPS | 3.56 | 1.82 | 0.29 | -16.26 | -2.35 | -0.91 | -3.64 | 0.38 | -2.20 | -0.50 | -1.45 | 1.21 | 1.36 |
| Owner EPS | 1.97 | 2.19 | -0.08 | -2.37 | -2.58 | -3.90 | -0.43 | -0.59 | 0.14 | 0.08 | 0.06 | 0.42 | -2.73 |
| Book Value | 27.17 | 34.44 | 29.68 | 17.08 | 14.41 | 12.73 | 9.15 | 9.37 | 7.02 | 6.71 | 4.75 | 6.79 | 7.07 |
| Cash Flow/Share | 5.97 | 6.41 | 3.46 | 2.19 | 2.40 | 0.68 | 1.11 | 0.73 | 1.43 | 1.22 | 1.10 | 1.42 | 5.40 |
| Dividends/Share | 1.34 | 1.36 | 1.36 | 0.85 | 0.01 | 0.05 | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 858.1M | 864.3M | 1.1B | 1.0B | 1.0B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.1B | 1.2B | 1.2B |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | 496.5 | N/A | N/A | N/A | N/A | 22.6 | N/A | N/A | N/A | 26.4 | 22.7 |
| P/FCF | N/A | N/A | 13.1 | 14.3 | 8.9 | 49.0 | 16.7 | 40.0 | 9.8 | 13.9 | 34.4 | 32.4 | 30.6 |
| EV/EBIT | N/A | N/A | 30.3 | N/A | N/A | N/A | N/A | 16.8 | N/A | 61.5 | N/A | 22.5 | 15.2 |
| Price/Book | N/A | N/A | 1.0 | 1.1 | 1.1 | 0.8 | 1.1 | 0.9 | 1.3 | 1.6 | 4.8 | 4.7 | 4.4 |
| Price/Sales | N/A | N/A | 2.2 | 1.1 | 1.2 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 1.1 | 1.3 | 22.5 |
| FCF Yield | N/A | N/A | 8.9% | 7.0% | 11.2% | 2.0% | 6.0% | 2.5% | 10.2% | 7.2% | 2.9% | 3.1% | 3.3% |
| Market Cap | 0 | 0 | 33.8B | 19.3B | 16.0B | 10.9B | 10.6B | 9.4B | 10.2B | 11.7B | 25.7B | 37.2B | 35.9B |
| Avg. Price | 0.00 | 0.00 | 48.74 | 25.30 | 20.92 | 11.54 | 10.43 | 10.11 | 8.65 | 9.16 | 15.90 | 18.97 | 30.81 |
| Year-End Price | 0.00 | 0.00 | 34.75 | 19.00 | 15.69 | 9.96 | 9.71 | 8.60 | 9.18 | 10.47 | 22.77 | 31.89 | 30.81 |
TEVA PHARMACEUTICAL INDUSTRIES LTD passes 3 of 9 quality checks, indicating weak fundamentals.
TEVA PHARMACEUTICAL INDUSTRIES LTD trades at 25.5x trailing earnings, compared to its 15-year median P/E of 24.5x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 31.3x vs a median of 15.5x. The company's 5-year average ROIC is 3.2% with a gross margin of 48.7%. At current prices, the estimated annualized return to fair value is +5.1%.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported annual revenue of $17.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a net profit margin of 8.2%. This is a modest margin.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) generated $1.1 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a debt-to-equity ratio of 0.82. This indicates moderate leverage.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported earnings per share (EPS) of $1.21 in its most recent fiscal year.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a return on equity (ROE) of 21.2%. This indicates the company generates strong returns for shareholders.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a 5-year average gross margin of 48.7%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a book value per share of $6.79, based on its most recent annual SEC filing.